Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
PEG-3350, SODIUM CHLORIDE, SODIUM BICARBONATE, POTASSIUM CHLORIDE AND BISACODYL vs AMIKIN IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Combination of osmotic laxative (PEG-3350, sodium chloride, sodium bicarbonate, potassium chloride) and stimulant laxative (bisacodyl). PEG-3350 causes water retention in colon, increasing stool water content and volume, stimulating peristalsis. Electrolytes maintain fluid/electrolyte balance. Bisacodyl stimulates colonic smooth muscle contraction and inhibits water absorption.
Aminoglycoside antibiotic that binds to the 30S ribosomal subunit, causing misreading of m RNA and inhibition of protein synthesis.
Cleansing of the colon as a preparation for colonoscopy in adults and pediatric patients,Colonoscopy preparation in patients with renal impairment or electrolyte abnormalities (off-label)
Treatment of serious gram-negative bacterial infections,Septicemia,Lower respiratory tract infections,Intra-abdominal infections,Complicated urinary tract infections,Skin and soft tissue infections,Bone and joint infections,Burn infections,Perioperative prophylaxis in high-risk patients
For colonoscopy preparation: Day 1: 4 bisacodyl tablets (5 mg each) orally at 2000. Day 2: 1 liter of PEG-3350 plus electrolytes solution (4 sachets dissolved in 4 liters water) orally at 0800; then 2 liters more over 3-4 hours. Alternatively, split-dose regimen: 2 liters evening before colonoscopy and 2 liters morning of procedure.
15 mg/kg/day IV divided every 8-12 hours (usual adult dose: 15 mg/kg/day).
PEG-3350: not applicable (non-absorbed). Bisacodyl: terminal half-life 8–16 hours; clinical effect peaks within 6–12 hours.
Terminal elimination half-life: 2–3 hours in patients with normal renal function; may be prolonged to 30–60 hours in anuria.
PEG-3350 is not metabolized; excreted unchanged in feces. Bisacodyl is metabolized in the liver and small intestine to its active metabolite, bis-(p-hydroxyphenyl)-pyridyl-2-methane, by ester hydrolysis. Electrolytes are absorbed or secreted by normal physiological mechanisms.
Primarily excreted unchanged by glomerular filtration. Minimal hepatic metabolism.
PEG-3350 is not absorbed, excreted unchanged in feces. Electrolytes (sodium chloride, sodium bicarbonate, potassium chloride) are absorbed and renally excreted; bisacodyl is primarily excreted as glucuronide conjugates in feces (biliary) and urine (renal). Approximately 95% of bisacodyl is recovered in feces, 5% in urine.
Renal excretion of unchanged drug via glomerular filtration; >90% eliminated unchanged in urine within 24 hours. Biliary/fecal excretion <1%.
PEG-3350: negligible (non-absorbed). Bisacodyl: ~90% bound to plasma proteins.
Low protein binding; 0–11% bound, primarily to albumin.
PEG-3350: not distributed (non-absorbed). Bisacodyl: Vd approximately 0.4–0.6 L/kg, indicating moderate tissue distribution.
Vd: 0.25–0.4 L/kg; approximates extracellular fluid volume. Increased in edema, ascites; decreased in dehydration.
PEG-3350: negligible systemic absorption (<0.2%). Bisacodyl: oral bioavailability 15–30% due to first-pass metabolism; rectal bioavailability ~50%.
Intravenous: 100% bioavailable. Not administered orally (negligible absorption).
Contraindicated in severe renal impairment (Cr Cl <30 m L/min) due to risk of electrolyte disturbances. In moderate impairment (Cr Cl 30-50 m L/min): use with caution, monitor electrolytes. No dose adjustment specified by manufacturer for mild impairment.
For GFR 30-59 m L/min: extend interval to every 12-24 hours; GFR 15-29 m L/min: every 24-48 hours; GFR <15 m L/min (not on dialysis): every 48-96 hours or consider dosing based on serum levels.
No specific dose adjustment required for hepatic impairment based on Child-Pugh class. However, use with caution in severe hepatic impairment due to potential for encephalopathy from electrolyte shifts.
No specific Child-Pugh based modifications; monitor renal function and drug levels.
Not FDA-approved for children <2 years. For children 2-11 years: PEG-3350 plus electrolytes 75-100 m L/kg/dose orally, up to 4 L, for colonoscopy preparation. Bisacodyl tablets: children 6-11 years: 2.5-5 mg orally at bedtime day before procedure. Weight-based: not standardized; refer to specific pediatric protocols.
Neonates: 15-20 mg/kg/day IV divided every 12 hours; Infants and Children: 15-22.5 mg/kg/day IV divided every 8-12 hours.
Use with caution due to increased risk of electrolyte imbalance and dehydration. No specific dose reduction recommended; however, consider lower volume (2 L) split-dose regimen. Monitor renal function and electrolytes before and after procedure.
Adjust dose based on renal function; monitor serum creatinine and trough levels; usual starting dose: 15 mg/kg/day with extended intervals per renal function.
WARNING: SERIOUS FLUID AND ELECTROLYTE ABNORMALITIES. There have been reports of significant fluid shifts, severe electrolyte abnormalities (including hypokalemia, hyponatremia), and dehydration in patients treated with this product. The risk is increased in patients with renal insufficiency, electrolyte abnormalities, or those taking concomitant medications that affect electrolytes. Monitor and correct fluid and electrolyte disturbances before use.
Aminoglycosides can cause nephrotoxicity and ototoxicity. Neurotoxicity (including vestibular and auditory) may occur even at normal doses. Risk is greater in patients with renal impairment, pre-existing hearing loss, or prolonged use. Monitor renal function and eighth cranial nerve function.
Risk of electrolyte abnormalities and dehydration; correct before use,Use with caution in patients with renal impairment, electrolyte disturbances, or taking diuretics, ACE inhibitors, or NSAIDs,Risk of serious arrhythmias due to electrolyte imbalance,Possible colonic mucosal ulcerations (aphthoid ulcers) with bisacodyl,Gag reflex may be impaired in elderly, debilitated, or patients with swallowing disorders; risk of aspiration,May cause Mallory-Weiss tear or esophageal perforation if vomiting occurs,Monitor for QT prolongation in at-risk patients
Monitor renal function and audiometric tests,Adjust dose based on renal function,Risk of neuromuscular blockade, especially in patients with neuromuscular disorders,Avoid concurrent use of other nephrotoxic or ototoxic drugs,Use caution in neonates, elderly, and patients with dehydration
Known hypersensitivity to any component,Gastrointestinal obstruction, ileus, gastric retention, bowel perforation, toxic colitis, toxic megacolon,Significant electrolyte abnormalities (e.g., severe hypokalemia, hyponatremia),Renal impairment (e.g., creatinine clearance < 30 m L/min) for formulations with high PEG-3350 content (note: this product contains lower PEG dose, but caution still warranted),Pregnancy (relative contraindication; use only if clearly needed),Patients with impaired consciousness
Hypersensitivity to amikacin or other aminoglycosides,Myasthenia gravis (relative due to risk of neuromuscular blockade)
Avoid solid foods, dairy, and red/purple colored liquids during preparation. Only clear liquids (water, clear broth, apple juice, gelatin, tea or coffee without cream) are permitted until after the procedure.
No clinically significant food interactions. Maintain adequate hydration. Avoid excessive alcohol consumption.
First trimester: Minimal systemic absorption; no known teratogenic effects. Second/third trimester: Avoid use due to risk of electrolyte imbalance and fluid shifts; not associated with congenital anomalies.
Aminoglycosides like amikacin cross the placenta. First trimester: No evidence of major malformations, but risk cannot be excluded. Second and third trimesters: Potential for fetal ototoxicity (eighth cranial nerve damage) and nephrotoxicity, especially with high doses or prolonged use. Avoid unless compelling indication.
Bisacodyl and polyethylene glycol are not excreted in breast milk in significant amounts; M/P ratio unknown. Minimal systemic absorption suggests low risk. Use with caution due to potential gastrointestinal effects in infant.
Minimal excretion into breast milk (M/P ratio unknown but expected low). No reports of adverse effects in nursing infants from maternal amikacin use. Caution with infant renal impairment or premature infants due to potential accumulation. Use only if necessary.
No standard dose adjustments established; avoid use in pregnancy due to lack of safety data. If used, standard dosing for bowel preparation should be individualized with close monitoring.
Increased renal clearance in pregnancy may lower serum levels; consider higher doses based on therapeutic drug monitoring. Adjust for renal impairment if present. Standard initial dosing: 15 mg/kg/day IV/IM divided q8-12h, with level-guided adjustments.
This combination is used for colonoscopy preparation. Ensure adequate hydration and renal function assessment; avoid in patients with ileus, GI obstruction, or significant electrolyte abnormalities. Bisacodyl is a stimulant laxative that may cause cramping. Administer in divided doses as per protocol.
Amikacin is an aminoglycoside antibiotic with concentration-dependent bactericidal activity. Monitor peak (20-30 mcg/m L) and trough (<10 mcg/m L) serum levels to optimize efficacy and minimize toxicity. Adjust dose based on renal function (Cr Cl). Ototoxicity (vestibular and cochlear) and nephrotoxicity are dose-limiting; audiometry and renal function tests are mandatory. Extended-interval dosing (15-20 mg/kg once daily) is preferred for most indications. Avoid concurrent use with other nephrotoxic drugs (e.g., vancomycin, loop diuretics).
Drink plenty of clear liquids to stay hydrated.,Follow the exact dosing schedule provided by your doctor.,Expect frequent, watery bowel movements; stay near a restroom.,Do not eat solid foods during the preparation; only clear liquids.,Notify your doctor if you experience severe abdominal pain, vomiting, or signs of dehydration.
Take exactly as prescribed; do not skip doses or stop early.,Drink plenty of fluids to stay hydrated.,Report hearing changes (ringing in ears, dizziness) immediately.,Report decreased urine output or swelling in legs.,Avoid taking other medications without consulting your doctor, especially pain relievers like ibuprofen.,This medication is given intravenously; you may feel warmth or tingling during infusion.
"Mycophenolic acid, a prodrug of mycophenolate mofetil, undergoes enterohepatic recirculation and is absorbed in the stomach and proximal small intestine. Sodium bicarbonate, by raising gastric pH, can reduce the dissolution and absorption of mycophenolic acid, leading to decreased systemic exposure and potentially reduced immunosuppressive efficacy. This interaction may increase the risk of transplant rejection when used concurrently."
"Sodium bicarbonate, an alkalizing agent, can increase the gastric pH, which may reduce the dissolution and absorption of topically administered clobetasol propionate if swallowed inadvertently. However, this interaction is not clinically significant for topical application, as systemic absorption of clobetasol is minimal. The theoretical decrease in bioavailability is unlikely to affect efficacy or safety."
"Perphenazine, a phenothiazine antipsychotic, can reduce the absorption of sodium bicarbonate by delaying gastric emptying and increasing gastrointestinal transit time. This results in decreased systemic availability of bicarbonate, potentially attenuating its alkalinizing effect and compromising its efficacy in conditions requiring urinary alkalinization or systemic acidosis correction."
"Lithium cation may increase the excretion rate of Sodium chloride which could result in a lower serum level and potentially a reduction in efficacy."
"The risk or severity of adverse effects can be increased when Sodium chloride is combined with Tolvaptan."
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about PEG-3350, SODIUM CHLORIDE, SODIUM BICARBONATE, POTASSIUM CHLORIDE AND BISACODYL vs AMIKIN IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER, answered by our medical review team.
PEG-3350, SODIUM CHLORIDE, SODIUM BICARBONATE, POTASSIUM CHLORIDE AND BISACODYL is a Electrolyte that works by Combination of osmotic laxative (PEG-3350, sodium chloride, sodium bicarbonate, potassium chloride) and stimulant laxative (bisacodyl). PEG-3350 causes water retention in colon, increasing stool water content and volume, stimulating peristalsis. Electrolytes maintain fluid/electrolyte balance. Bisacodyl stimulates colonic smooth muscle contraction and inhibits water absorption.. AMIKIN IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER is a Electrolyte that works by Aminoglycoside antibiotic that binds to the 30S ribosomal subunit, causing misreading of m RNA and inhibition of protein synthesis.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between PEG-3350, SODIUM CHLORIDE, SODIUM BICARBONATE, POTASSIUM CHLORIDE AND BISACODYL and AMIKIN IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER depend on the specific clinical indication. These are both Electrolyte agents and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of PEG-3350, SODIUM CHLORIDE, SODIUM BICARBONATE, POTASSIUM CHLORIDE AND BISACODYL is: For colonoscopy preparation: Day 1: 4 bisacodyl tablets (5 mg each) orally at 2000. Day 2: 1 liter of PEG-3350 plus electrolytes solution (4 sachets dissolved in 4 liters water) orally at 0800; then 2 liters more over 3-4 hours. Alternatively, split-dose regimen: 2 liters evening before colonoscopy and 2 liters morning of procedure.. The standard adult dose of AMIKIN IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER is: 15 mg/kg/day IV divided every 8-12 hours (usual adult dose: 15 mg/kg/day).. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between PEG-3350, SODIUM CHLORIDE, SODIUM BICARBONATE, POTASSIUM CHLORIDE AND BISACODYL and AMIKIN IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. PEG-3350, SODIUM CHLORIDE, SODIUM BICARBONATE, POTASSIUM CHLORIDE AND BISACODYL is classified as Category A/B. First trimester: Minimal systemic absorption; no known teratogenic effects. Second/third trimester: Avoid use due to risk of electrolyte imbalance and fluid shifts; not associated . AMIKIN IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER is classified as Category A/B. Aminoglycosides like amikacin cross the placenta. First trimester: No evidence of major malformations, but risk cannot be excluded. Second and third trimesters: Potential for fetal. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.